-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the iHuPDX platform?
Author:
InnoModels
Release time:
2024-05-22
With its profound accumulation and continuous innovation in the field of biomedicine,InnoModels Biotechnology has successfully launched the iHuPDX platform. With its unique advantages, this platform has revolutionized individualized tumor research and treatment.
The core feature of iHuPDX platform is its xenotransplantation technology based on patients' individual tumor cells. Through the fine collection and processing of patient cancer tissue samples, the platform is able to transplant these cells into animals such as mice to form highly individualized transplanted tumors. The successful implementation of this technology allows researchers to conduct in-depth studies of tumor growth, development and drug response in an environment that is closer to the actual patient situation.
First, the iHuPDX platform is highly individualized. Since it is a disease model based on individual patient's tumor cells, it is able to better reflect the patient's tumor characteristics. The establishment of such individualized models not only contributes to a more comprehensive understanding of a patient's tumor biology, but also provides strong support for precision medicine. Through in-depth study of these models, doctors can more accurately determine a patient's condition and develop a more personalized treatment plan.

Second, the iHuPDX platform shows great potential in drug response prediction. Due to the highly individualized nature of the models, the platform can be used to test the response of different drugs to a specific patient's tumor. This feature provides strong support for the development of personalized treatment plans and helps doctors choose more effective drugs with fewer side effects for their patients. Meanwhile, through the prediction of drug response, potential drug resistance problems can also be detected in advance, providing an important reference for the adjustment of treatment programs.
In addition, the iHuPDX platform provides a new perspective for cancer research. By comparing the tumor heterogeneity between different patients, researchers can gain a deeper understanding of the diversity of cancer and reveal the mechanisms of its occurrence and development. This shift in perspective not only helps to promote the development of cancer research, but also provides an important theoretical basis for the development of individualized treatment strategies.
The iHuPDX platform also excels in model stability and growth rate. The platform uses primary cell inoculation technology to ensure homogenization of samples between batches through cell suspension modeling. This ensures a high degree of consistency in the growth rate and biological characteristics of samples from the same batch, laying a solid foundation for model stability. Meanwhile, the platform also realizes the early and uniform growth of transplanted tumors by optimizing the culture conditions and transplantation technology, which provides the best experimental window for drug efficacy experiments.
In summary, the iHuPDX platform of InnoModels Biotechnology provides strong support for individualized tumor research and treatment with its highly individualized disease model, accurate drug response prediction capability, and a new perspective on cancer research. With the continuous development and improvement of this platform, it is believed that it will bring benefits to more tumor patients in the future and promote the advancement of medical career.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd